This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
GSK and Flagship to jointly fund up to $150 million upfront
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
